Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
EMERYVILLE, Calif., Feb. 22 /PRNewswire/ -- Adamas
Pharmaceuticals, Inc., a privately held company, reported today on
the publication of results from a preclinical study that
demonstrated the synergistic effects of triple combination
antiviral drug (TCAD) therapy against multiple strains of seasonal,
pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus,
including three strains of amantadine resistant pandemic H1N1 and
two strains of oseltamivir resistant seasonal H1N1.
The results of this study have been published in PLoS One under
the title: Triple Combination of Amantadine, Ribavirin, and
Oseltamivir is Highly Active and Synergistic Against Drug Resistant
Influenza Virus Strains In Vitro. PLoS One is an interactive
open-access journal for the communication of all peer-reviewed
scientific and medical research published by the Public Library of
Science (PLoS). Interested parties may view the article on the PLoS
website under Presentations and Publications.
The data demonstrated that amantadine, ribavirin and
oseltamivir, when administered as components of a triple
combination therapy, had a synergistic effect (i.e. enhanced
antiviral activity) against multiple amantadine- and
oseltamivir-resistant virus strains. The data also demonstrated
that the antiviral activity of the TCAD regimen is greater than the
antiviral activity of any double combination. Further, when
investigating amantadine-resistant virus strains against which
amantadine had no significant antiviral activity as a single agent,
the addition of amantadine at clinically relevant concentrations to
the combination of ribavirin and oseltamivir resulted in a dose
dependent inhibition of virus replication. This was similarly
observed for oseltamivir in strains that were oseltamivir
resistant. These data demonstrate that the TCAD therapy may have
broad-spectrum activity against the circulating resistant influenza
A strains, including novel influenza A/H1N1, the pandemic influenza
strain.
"Given the fact that the majority of influenza A viruses are
resistant to at least one antiviral, these data suggest the
advantage of a triple combination drug therapy approach over double
combinations or monotherapy," said Gregory Went, Ph.D., chief
executive officer and chairman of Adamas. "We are encouraged about
the potency of TCAD therapy measured in preclinical studies and
look forward to continued validation of TCAD therapy with our
academic and clinical partners."
About TCAD
Adamas is pioneering triple combination antiviral drug (TCAD)
therapy for influenza, which is designed to inhibit viral
replication at multiple points in the virus proliferation pathway.
TCAD therapy includes Adamas' investigational proprietary
fixed-dose combination of amantadine and ribavirin, to be
administered adjunctively with a neuraminidase inhibitor such as
Tamiflu ® (oseltamivir phosphate, Roche). Preclinical data
indicate that the in vitro combination of these drugs, each with
their own mechanism of action, act synergistically to provide a
much higher level of antiviral activity than single or double drug
combination therapies. In in vitro studies to date, TCAD therapy
also has been found to provide greater antiviral activity across
multiple strains of influenza, even those resistant to single
pharmaceutical agents. TCAD therapy for influenza A is currently
being investigated in a Phase 2 human clinical study.
About Adamas
Adamas is an emerging pharmaceutical company focused on
developing small molecule Advantaged Therapeutics to treat
neurological and infectious diseases, including influenza A, the
cause of the current flu pandemic. Adamas' approach to
pharmaceutical development is to identify synergistic drug
mechanisms that can be developed as optimized combination drug
therapies to increase safety, efficacy and compliance, thus
improving upon the standard of care. Adamas is headquartered in
Emeryville, California, with operations in Bangalore, India. For
more information about Adamas, please visit
www.adamaspharma.com.
Source: Adamas Pharmaceuticals, Inc.
CONTACT: Kimberly Kraemer, Corporate Communications,
Adamas
Pharmaceuticals, +1-510-450-3572
Web Site: http://www.adamaspharma.com/
Posted: February 2010
